David John Simpson

MedImmune Ltd. engages in research, development and exploitation of products in the field of molecular engineering. The company was founded on December 11, 1989 and is headquartered in Cambridge, the United Kingdom.

Domantis Ltd. develops domain antibody therapeutics for treating highly unmet diseases. It enables DABS to serve as building blocks for therapeutics simultaneously directed at more than one disease target. The company was founded in December 2000 and is headquartered Middlesex, the United Kingdom.

Part of Istesso Ltd., Modern Biosciences Ltd. is a British pharmaceutical company that manufactures pharmaceutical products. The company is based in London, UK. The company was founded by Samuel Cameron Williams, Alexander James Stevenson. Samuel Cameron Williams has been the CEO since incorporation.

ReNeuron Ltd. researches and develops drugs, diagnostics, and other therapeutic products. The company was founded on May 23, 1997 and is headquartered in Bridgend, the United Kingdom.

PolyTherics Ltd. develops biomedical polymers for therapeutic applications. The company was founded by Antony Godwin, Sunil Shaunak and Steve Brocchini in 2001 and is headquartered in Babraham, the United Kingdom.

Kuur Therapeutics provides clinical cellular therapeutics services. It develops, manufactures and markets personalized cellular immunotherapeutics for infectious disease and cancer. Cell Medica has developed proprietary production technology enabling GMP compliant manufacture of antigen-specific T cells. The company was founded by Gregg Sando in 2006 and is headquartered in London, the United Kingdom.

Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom.

Akamis Bio Ltd. operates as a biotechnology company which develops novel therapeutics that addresses cancer and other clinically unmet diseases. Its products include Enadenotucirev, Espindolol and AbEnAd. The firm also develops treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines. The company was founded by Andrew Justin Stewart Coats and Stefan D. Anker on November 17, 2006 and is headquartered in Abingdon, the United Kingdom.

Parkwalk Advisors Ltd. (Parkwalk Advisors) is a venture capital firm founded in 2009 by Moray Wright and Alastair Hugh Lowell Kilgour. The firm is headquartered in London, United Kingdom.

Part of Avacta Group Plc, Aptuscan Ltd. provides biotechnology research in the development of various products. The company is based in Leeds, UK. Aptuscan was acquired by Avacta Group Plc on January 10, 2012 for $2.50 million.

Ossianix, Inc. develops single domain antibodies. It develops biotherapeutic products using the versatile single domain VNAR antibody from the shark and also developed highly innovative approaches to target specific cells and tissues such as the brain via the blood brain barrier and peripheral nerve via the neuromuscular junction. The company was founded by Frank S. Walshin, J. Lynn Rutkowski and Corey S. Goodman in 2011 and is headquartered in Philadelphia, PA.

Ieso Digital Health Ltd. provides Internet enabled mental health services to health providers, private individuals and businesses. The firm engages in delivering cognitive behavioral therapy. It offers anxiety, bereavement, child and family, depression, drug and alcohol misuse, eating disorder, managing anger, managing pain, obsessive compulsive disorder, panic, phobia, post traumatic stress, relationship, sexual difficulty, sports psychology, stress management, and terminal illness therapy services. The company was founded by Barnaby Perks, Sue Wright and Nadine Field in 2000 and is headquartered in Cambridge, the United Kingdom.

Part of Resilient (Holdings) Plc, Smartnumbers is a British company that specializes in contact centre fraud prevention, business continuity and transformation. The company is based in London, UK. The company's main focus is to make voice communications safer by ensuring networks stay secure, reliable and compliant. The company was founded in 1978. The CEO is Jamie Melling.

Pulmocide Ltd. provides biopharmaceutical services. It develops inhaled medicines for viral and fungal infections of the respiratory tract. The company was founded by William Garth Rapeport, John Murray, Kazuhiro Ito, and Peter Strong on March 23, 2007 and is headquartered in London, the United Kingdom.

Aqdot Ltd. develops novel fabrication technology for smart capsules. Its technology simplifies the encapsulation process by utilizing the novel one-step, "shrink-wrap" approach based on a combination of emulsion technology and supramolecular chemistry. The company was founded by Jing Zhang, Chris Abell, Oren Scherman, and Roger Coulston in 2012 and is headquartered in Cambridge, the United Kingdom.

Genomics Plc develops research and experimental development on biotechnology. It develops and applies cutting edge analysis and algorithms to database of genomic and phenotypic data to uncover the relationships between genetic variation and human disease. The company was founded by Peter Donnely, Gil McVean, Chris Spencer and Gerton Lunter on January 10, 2004 and is headquartered in Oxford, the United Kingdom.

Spectral Edge Ltd. develops image fusion technology. Its products include PHUSION for photography, multispectral vision and video personalization. The company was founded by Robert Edward Meredith Swann, David Connah, Graham D. Finlayson, Mark S. Drew and Joita Dey in February 2011 and is headquartered in Cambridge, the United Kingdom.

Modern Biosciences Nominees Ltd. acts as a nominee, trust, and depository.

BliNK Biomedical SAS is a French company that specializes in cutting-edge technology for identifying rare antibody-secreting cells from humans and other species. The company is based in Marseille, France. The company's technology is based on validated platforms, isaac and vivascreen, which provide a highly efficient and deep mining process. The CEO of the company is Jack Elands.

Gammadelta Therapeutics Ltd. is developing the potential of gamma delta (?d) cells to create improved immunotherapy of cancer and other serious diseases. The company was founded by Raj Mehta in 2016 and is headquartered in London, the United Kingdom.

Microbiotica Ltd. performs research and experimental development on biotechnology. The company was founded by Michael Anthony Romanos, Trevor David Lawley and Gordon Dougan in December 2016 and is headquartered in Cambridge, the United Kingdom.

Avacta Life Sciences Ltd. provides powerful reagents for research and diagnostics. The company is headquartered in Wetherby, the United Kingdom.

Istesso Ltd. Operates as a drug discovery and development company. The company was founded in 2017 and is headquartered in London, the United Kingdom.

Part of Convergys Capital Ltd., Novalgen Ltd. is a clinical stage immunology company based in Northwood Hills, UK. Novalgen is developing breakthrough immunotherapies for people with immunologically driven diseases using their autoregulation platform. The British company's lead program, NVG-111, is an ROR1-targeting bispecific antibody T-cell engager for the treatment of both hematological malignancies and solid tumors using their breakthrough bispecific antibody technology. The company's lead AR program, NVG-222, builds on the success of NVG-111 and is primed for entry into the clinic in 2024. The company was founded by Amit Chunilal Nathwani and has been the CEO since incorporation.